JTE-907 

JTE-907 is a selective and orally active cannabinoid CB2 receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis^[1][2][3][4].

JTE-907 (1-10 μM; 4-20 h) upregulates pro-inflammatory and angiogenic gene expression and IL-6 secretion in mature human subcutaneous adipocytes via CB₁ and TRPV1 receptors^[2].
JTE-907 (10 μM; 20 h) downregulates CB₁, MCP-1, and IL-1β gene expression in human subcutaneous preadipocytes^[2].
JTE-907 (0.1 μM; 20 h) reverses the CB2 receptor-mediated protective effects of Anandamide (HY-10863) and JWH-015 against cytokine-induced colitis-like damage in healthy human colonic mucosal explants, including restoring crypt damage, luminal epithelial damage, and lamina propria lymphocyte density to levels comparable to cytokine-only treatment^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JTE-907 (0.01-10 mg/kg; p.o.; single dose 1 h pre-2-AG-E exposure) inhibits both early and late 2-AG-E-induced cutaneous ear swelling in female BALB/c mice, with partial dose-dependent suppression of the late response at lower doses^[1].
JTE-907 (0.01-10 mg/kg; p.o.; single dose 1 h pre-arachidonic acid exposure) does not inhibit arachidonic acid-induced cutaneous ear swelling in female BALB/c mice^[1].
JTE-907 (0.1-10 mg/kg; p.o.; once daily for 6 days plus two doses around the 4th DNFB exposure) significantly suppresses DNFB-induced allergic dermatitis ear swelling in female BALB/c mice without inducing systemic immunosuppression-related changes to spleen or thymus weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

438.47

C₂₄H₂₆N₂O₆

282089-49-0

Solid

Off-white to light yellow

O=C(C1=CC2=C(NC1=O)C(OCCCCC)=C(OC)C=C2)NCC3=CC=C(OCO4)C4=C3

Room temperature in continental US; may vary elsewhere.

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Ueda Y, et al. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol. 2005;520(1-3):164-171.  [Content Brief]

  [2]. González-Muniesa P, et al. Upregulation of the expression of inflammatory and angiogenic markers in human adipocytes by a synthetic cannabinoid, JTE-907. Horm Metab Res. 2010;42(10):710-717.

  [3]. Kampa KM, et al. Delta9-Tetrahydrocannabinol induces apoptosis via Cannabinol Receptor 1 and modulates methylation of oncogenes and tumorsuppressors in blasts derived from patients with acute lymphoblastic or myeloid leukemia. Cancer Res. 2012;72(8_Supplement):4658.

  [4]. Harvey BS, et al. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine. 2013;63(2):209-217.